Crescent Biopharma, Inc. (CBIO)

Crescent Biopharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024
Period Ending	Dec 31, 2024
Net Income	-71.47
Asset Writedown & Restructuring Costs	4
Stock-Based Compensation	4.54
Other Operating Activities	0.01
Change in Accounts Payable	29.31
Change in Other Net Operating Assets	8.54
Operating Cash Flow	-25.08
Total Debt Issued	149.92
Net Debt Issued (Repaid)	149.92
Issuance of Common Stock	1.26
Other Financing Activities	-3.04
Financing Cash Flow	164.14
Net Cash Flow	139.06
Change in Working Capital	37.85

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q